[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-transplant":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,73,96,123,147,173,194,217,238,260,281,302,328,338,366,388],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053546","the-effect-of-the-reflux-band-upper-esophageal-sphincter-ues-assist-device-on-reflux-for-lung-transplant-recipients-100053546",false,"NCT03886961","The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients","Reflux Band","Inclusion Criteria:\n\n* Clinically stable lung transplant patients(single lung, double lung, or re-transplant) as defined by stable FEV1 over the prior two visits\n* 13 Abnormal pH impedence or esophagram or documented gastric reflux at pre-transplant evaluation\n* Patient must be willing and able to provide informed consent\n* Understands the clinical study requirements and is able to comply with follow-up schedule\n\nExclusion Criteria:\n\n* Currently being treated with another investigational medical device and\u002For drug\n* Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP)\n* Previous head or neck surgery \u002F radiation\n* Carotid artery disease, thyroid disease, or history of cerebral vascular disease\n* Nasopharyngeal cancer\n* Suspected esophageal cancer","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","A prospective, open label, study designed to assess the affect of the Reflux Band® UES Assist Device (Reflux Band) on reflux in patients that have undergone lung transplantation.",[27,28],"Lung Transplant","GERD","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2019-05-17",{"date":37,"type":21},"2027-12-20",{"name":39,"class":40},"University of Florida","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100518642","phase-2-tocilizumab-in-lung-transplantation-100518642","NCT06033196","Tocilizumab in Lung Transplantation","Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Tocilizumab (CTOT-45)","ALL IN LUNG","Inclusion Criteria:\n\nStudy Entry:\n\n1. Subject and\u002For parent guardian must be able to understand the purpose of the study and willing to participate and sign informed consent\u002Fassent\n2. Greater than or equal to 30 kg body weight\n3. Listed or received for a primary lung transplant\n4. No previous or planned desensitization therapy prior to transplant\n5. Serum Immunoglobulin G (IgG) level greater than 400 mg\u002FdL. Patients treated with intravenous immune globulin (IVIG) for hypogammaglobulinemia are eligible for enrollment if their serum IgG level is greater than 400 mg\u002FdL 14 or more days after the most recent IVIG treatment\n6. For women of child-bearing potential, willingness to use highly-effective contraception; according to the Food and Drug Administration (FDA) Office of Women's Health (http:\u002F\u002Fwww.fda.gov\u002Fbirthcontrol).\n\n   Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study. Those who choose oral contraception must agree to use a second form of contraception after administration of study drug for a period of 1 year after the last dose of study drug\n7. Tested negative for latent TB infection (LTBI) using a PPD or interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB) within 1 year prior to transplant or has completed appropriate LTBI therapy within the 1 year prior to transplant\n8. Vaccinations must be up to date per the Division of Allergy, Immunology, and Transplantation (DAIT) Guidance for Patients in Transplant Trials\n\nRandomization:\n\n1. Provide written informed consent for the study participation, and agree to continue in the study\n2. Received a single or bilateral lung transplant\n3. Agreement to use contraception; according to the FDA Office of Women's Health (http:\u002F\u002Fwww.fda.gov\u002Fbirthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study. Those who choose oral contraception must agree to use a second form of contraception after administration of study drug for a period of 1 year after the last dose of study drug\n4. Negative physical crossmatch at the time of transplant or a crossmatch result that did not require specific treatment per the site's clinical protocol\n5. Underwent bronchoscopy and found to have satisfactory bronchial anastomotic healing\n6. No desensitization therapy prior to transplant\n7. Negative pregnancy test (serum or urine) for women of child-bearing potential within 48 hours prior to randomization\n8. Recipient of lungs that have been supported with ex vivo lung perfusion (EVLP) devices are permitted\n\nExclusion Criteria:\n\nStudy Entry:\n\n1. Listed for multi-organ transplant (e.g., heart-lung, liver-lung, kidney-lung)\n2. Prior history of allogeneic organ or cellular transplantation\n3. Received treatment to deplete Human Leukocyte Antigens (HLA) antibodies before transplantation\n4. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period\n5. History of severe allergic and\u002For anaphylactic reactions to humanized or murine monoclonal antibodies\n6. Known hypersensitivity or previous treatment with ACTEMRA(R) (tocilizumab) within the last 3 months\n7. Infection with human immunodeficiency virus (HIV)\n8. Hepatitis B virus surface antigen or core antibody positive\n9. Hepatitis C virus PCR positive (HCV+) patients who have failed to demonstrate sustained viral remission (2 consecutive PCR or Nucleic Acid Tests (NAT) negative tests at least 24 weeks apart), with or without anti-viral treatment;\n10. Chronic infection with Burkholderia cenocepacia or Burkholderia gladioli\n11. Non-tuberculous mycobacterial (NTM) pulmonary disease; if there is a history of NTM pulmonary disease, culture conversion is necessary for eligibility\n12. Presence of active malignancy or history of malignancy less than 5 years in remission, excluding adequately treated in-situ cervical carcinoma, low grade prostate carcinoma, or adequately treated basal or squamous cell carcinoma of the skin\n13. History of hemolytic-uremic syndrome\u002F thrombotic thrombocytopenia purpura\n14. History of demyelinating disorders (e.g., multiple sclerosis, chronic inflammation demyelinating polyneuropathy)\n15. Current treatment with alkylating agents such as cyclophosphamide\n16. History of gastrointestinal (GI) tract perforation\n17. History of inflammatory bowel disease except fully excised ulcerative colitis\n18. Any history of diverticulitis (event if not perforated) or confirmed diverticular bleeding. (Diverticulosis is not an exclusion).\n19. Patients with a platelet count \\\u003C 100,000\u002Fmm\\^3 (last measurement within 7 days prior to enrollment)\n20. Patients with an absolute neutrophil count (ANC) \\\u003C 2,000\u002Fmm\\^3 (last measurement within 7 days prior to enrollment)\n21. Patients with Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels \\>3 times upper limit of normal\n22. Patients who use illegal drugs\n23. Smoking or vaping within 6 months of listing for transplant\n24. Use of investigational drugs within 4 weeks prior to enrollment\n25. Any condition that in the opinion of the site Principal Investigator (PI) introduces undue risk by participating in this study\n\nRandomization:\n\n1. Recipient of multi-organ or tissue transplants\n2. Clinically stable, without clinical evidence of untreated infection\n3. Received a live virus vaccine within 30 days prior to randomization\n4. Received treatment to deplete HLA antibodies before transplantation to improve the possibility of transplantation\n5. Patients with known donor-specific antibody that will require intervention based on local clinical protocols\n6. History of GI tract perforation\n7. History of inflammatory bowel disease except fully excised ulcerative colitis\n8. History of diverticulitis (diverticulosis is not an exclusion) or diverticular bleeding\n9. History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies\n10. Known hypersensitivity to ACTEMRA® (tocilizumab)\n11. Previous treatment with ACTEMRA® (tocilizumab) within the last 3 months.\n12. Recipient or donor with infection with human immunodeficiency virus (HIV)\n13. Recipient with hepatitis B virus surface antigen or hepatitis B core antibody positive\n14. Hepatitis B negative transplant recipient that received a transplant from a Hepatitis B core antibody positive donor unless the recipient has a Hepatitis B Surface Antigen (HBsAb) titer \\>10U\u002FL\n15. Recipient of a hepatitis C virus nucleic acid test (NAT) positive donor organ\n16. Latent TB infection (LTBI) and has not completed appropriate therapy\n17. Chronic infection with Burkholderia cenocepacia or Burkholderia gladioli\n18. Non-tuberculous mycobacterial (NTM) pulmonary disease; if there is a history of NTM pulmonary disease, culture conversion is necessary for eligibility\n19. Presence of active malignancy (except for non-melanoma skin cancer)\n20. History of hemolytic-uremic syndrome\u002F thrombotic thrombocytopenia purpura\n21. History of demyelinating disorders (e.g., multiple sclerosis, chronic inflammation demyelinating polyneuropathy)\n22. Current treatment with alkylating agents such as cyclophosphamide\n23. Patients with AST or ALT levels \\> 1.5 times upper limit of normal (last measurement within 1 day prior to randomization)\n24. Patients with platelet count \\\u003C100,000\u002Fmm\\^3 (last measurement within 1 day prior to randomization)\n25. Patients with an absolute neutrophil count (ANC) \\\u003C2,000\u002Fmm\\^3 (last measurement within 1 day prior to randomization)\n26. Patients who are administered anti-thymocyte globulin as induction therapy in the immediate post- transplant period\n27. Patients who have been treated in the past 3 months, or for whom it is anticipated that treatment with any immunomodulatory biological agents post-transplant are excluded\n28. Use of an investigational drug after transplant\n29. Smoking or vaping since enrollment\n30. Any condition that in the opinion of the site PI introduces undue risk by participating in this study","12 Years","75 Years",{"count":53,"type":21},350,[55],"PHASE2","This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids).\n\nThe primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death",[27],[27,59,60,61],"Tocilizumab","Immunosuppression","ACTEMRA","2026-06-12",{"date":64,"type":33},"2026-06-16",{"date":66,"type":33},"2024-02-13",{"date":68,"type":21},"2029-01-08",{"name":70,"class":71},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",21,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},"100632645","graft-20-a-multimodal-prospective-approach-to-define-the-mechanisms-and-clinical-features-of-acute-and-chronic-rejection-in-lung-transplantation-100632645","NCT07516379","GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with study procedures and availability for the duration of the study.\n2. Male or female, aged 18 - 75 years of age.\n3. Have progressive lung disease or undergone or being evaluated for lung transplantation.\n4. Ability of subjects to understand the informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. Pregnancy or lactation",{"count":80,"type":21},100,"OBSERVATIONAL","Background:\n\nLung transplants can save lives, but the procedure has risks. Some people develop donor-specific antibodies (DSA) after the procedure-that is, their bodies create proteins that treat the new lungs as foreign and mount an immune response against them. This is called rejection. But not everyone who has a transplant develops DSA, and not everyone who has DSA develops rejection. Researchers want to understand why.\n\nObjective:\n\nTo collect data to try to find out why some people develop rejection after lung transplants while others do not.\n\nEligibility:\n\nPeople aged 18 to 75 years who have progressive lung disease or undergone or may undergo a lung transplant.\n\nDesign:\n\nParticipants will have clinic visits every 3 to 6 months for up to 4 years. Some visits might require an overnight stay.\n\nEach visit will include multiple tests and procedures:\n\nPhysical exam with blood and urine tests. Some blood will be used for genetic testing.\n\nImaging scans. Participants will have 2 types of scan to get images of their lungs. For one, they will have a contrast agent given through a tube inserted into a vein.\n\nSix-minute walk test. Participants will walk back and forth in a hallway at their own pace. Researchers will check on how their body responds.\n\nLung function test. Participants will breathe into a tube connected to a machine.\n\nTwo other tests are optional:\n\nBronchoscopy with washings (lavage). A long tube with a light will be threaded down through the participant s nose or mouth and into their lungs.\n\nEndomicroscopy. During the bronchoscopy a tiny camera may be used to take pictures inside the lungs.\n\n...",[27,84,85],"End Stage Lung Disease","Rejection",[27,85],"2026-06-10",{"date":89,"type":33},"2026-06-11",{"date":91,"type":33},"2026-05-11",{"date":93,"type":21},"2032-03-27",{"name":95,"class":71},"National Heart, Lung, and Blood Institute (NHLBI)",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100552672","phase-2-belumosudil-to-block-chronic-lung-allograft-dysfunction-clad-in-high-risk-lung-transplant-recipients-100552672","NCT06476132","Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients","Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients: A Randomized, Multicenter, Double Blind, Placebo-Controlled Trial (CTOT-47)","CLAD","Inclusion Criteria:\n\n1. Participant and\u002For parent or guardian must be able to understand the purpose of the study, willing to participate, sign the informed consent, and if applicable assent.\n2. Single or bilateral lung transplant recipient age ≥ 12 years\n3. A qualifying biopsy obtained 60 to 550 days after lung transplant with evidence of allograft injury histology; a qualifying biopsy must have one or more of the following features alone or in combination: Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP), or Acute Lung Injury (ALI). The presence of any grade AR (A1 or greater) or LB (B1 or greater) qualifies for inclusion\n4. Females of reproductive potential and males with female partners of reproductive potential must agree to use effective contraception during treatment with belumosudil or placebo and for at least 3 months after the last dose. Participants must agree to refrain from donating or cryopreserving sperm, eggs (ova or ovocytes) for the purpose of reproduction during treatment with belumosudil or placebo and for at least 3 months after the last dose.\n5. Meeting hematologic laboratory criteria: absolute neutrophil count (ANC) \\>= 0.5 x 10(9)\u002FL and platelet count \\>= 50 x 10(9)\u002FL within 30 days of enrollment\n6. Meeting all blood chemistry laboratory criteria: aspartate aminotransferase (AST) or alanine transaminase (ALT) \\\u003C 2x upper limit of normal (ULN), bilirubin \\\u003C 1.5x ULN unless due to Gilbert's syndrome, estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73m2 within 30 days of enrollment\n7. Cytomegalovirus (CMV) polymerase chain reaction (PCR) negative within 30 days of enrollment\n8. In the absence of contraindications, must have received adult vaccinations or documented immunity as outlined in current National Institute of Allergy and Infectious Diseases (NIAID) Division of Allergy, Immunology, and Transplantation (DAIT) Guidance for Patients in Transplant Trials\n9. Receiving Calcineurin Inhibitor (CNI)-based maintenance Immunosuppression (IS) regimen\n\nExclusion Criteria:\n\n1. Multi-organ transplants involving more than one organ type (e.g., heart-lung)\n2. Prior organ transplant or prior bone marrow transplant\u002Fhematopoietic stem cell transplantation\n3. Greater than 120 days after a qualifying biopsy\n4. Clinical AMR prior to enrollment. Subclinical AMR is permitted if 90 days or greater prior to enrollment.\n5. Diagnosed with probable or definite CLAD according to International Society for Heart and Lung Transplantation (ISHLT) guidelines prior to enrollment.\n6. Posttransplant treatment with anti-thymocyte globulin within 30 days or alemtuzumab or any other prohibited medication within 90 days prior to enrollment.\n7. Epstein-Barr virus (EBV) seronegative recipient who received EBV positive donor lung(s).\n8. Treatment with any other investigational pharmacologic agent within 30 days prior to enrollment.\n9. Significant active uncontrolled infection which, in the opinion of the investigator, would place the participant at increased risk.\n10. Current use of sirolimus or everolimus.\n11. Recipient human immunodeficiency virus (HIV) positive.\n12. Recipient Hepatitis B surface antigen positive or Hepatitis B core antibody positive.\n13. Received lung(s) from a donor with known Hepatitis B virus (HBV) including Hepatitis B core antibody positive donors.\n14. Recipient history of Hepatitis C, Hepatitis C seropositive, or received lung(s) from a donor with known Hepatitis C (participants who have 3 months of documented consecutive undetected Hepatitis C virus PCR after treatment or spontaneous clearance will not be excluded).\n15. History of clinically significant surgical factors (such as phrenic nerve damage, transplant lung resection, chest wall surgery), or mechanical factors (such as posttransplant airways disease including bronchial dehiscence, stenosis, dilation, or stent placement, pleural disease) that impedes lung function.\n16. Past or current medical problems, psychosocial concerns, or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose undue risk from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.\n17. Pregnant or breastfeeding",{"count":105,"type":21},234,[55],"The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as \"Qualifying Biopsies\"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD.\n\nThe primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.",[27],[27,110,102,111,112,113,114],"Belumosudil","Acute Rejection","Lymphocytic Bronchiolitis","Organizing Pneumonia","Acute Lung Injury",{"date":116,"type":33},"2026-05-12",{"date":118,"type":33},"2025-03-12",{"date":120,"type":21},"2027-06-30",{"name":70,"class":71},12,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100481338","a-study-of-venoarterial-ecmo-vs-off-pump-bilateral-orthotopic-lung-transplantation-100481338","NCT05547698","A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation","Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation VIP BOLT Trial: A Multicenter Prospective Randomized Trial","Inclusion Criteria:\n\n* Bilateral Lung Transplantation (LTx) recipients.\n* Mean pulmonary artery pressure \\\u003C or = 35 mmHg.\n* Eligible for off-pump or VA ECMO based on the judgement of the attending surgeon.\n\nExclusion Criteria:\n\n* Single lung transplant\n* Multiorgan transplant.\n* Donor after cardiac death (DCD).\n* Re-transplant.\n* Intention to use prophylactic post-operative ECMO.\n* Previous major lung surgery. Video-assisted thoracoscopic surgery (VATS) and wedge resection are not an exclusion criterion.\n* Previous pleurodesis.\n* Preoperative ECMO and\u002For mechanical ventilation.",{"count":131,"type":21},228,[24],"The purpose of this research study is to compare the technique of performing bilateral lung transplantation off-pump vs venoarterial ECMO (VA ECMO). The goal of the trial is to determine which technique has lower rates of primary graft dysfunction.",[27],[136],"Bilateral","2026-04-27",{"date":139,"type":33},"2026-05-01",{"date":141,"type":33},"2022-09-17",{"date":143,"type":21},"2027-09",{"name":145,"class":40},"Mayo Clinic",3,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100634334","phase-2-targeting-interferon-gamma-with-emapalumab-to-lung-transplant-recipients-with-interferon-gamma-high-acute-lung-allograft-dysfunction-100634334","NCT07538336","Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction","TIGER-Lung","Inclusion Criteria:\n\n* Recipients ≥10 months post-lung transplant who are enrolled in existing biorepository study (IRB #13-10738) will be approached if they have ALAD and elevated AI2 and CXCL9 levels\n* Age: ≥18 years old\n* Informed Consent: Ability to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Active Bacterial Infection: Positive bacterial cultures from bronchoalveolar lavage (BAL) samples at the time of ALAD diagnosis. Viral infections, which are typically treated in lung transplant recipients with a steroid taper and cleared by type I interferons, are not exclusion criteria per se.\n* Active CMV or EBV Infection: Active reactivation of cytomegalovirus (CMV) or Epstein-Barr virus (EBV) based on plasma PCR testing.\n* Severe Comorbidities: Presence of severe conditions likely to compromise study participation or outcomes (e.g., terminal illness).\n* Pregnancy or Breastfeeding: Women who are pregnant or breastfeeding at the time of screening.\n* Concurrent Immunosuppressive Therapy Trials: Use of investigational agents or therapies other than standard of care post-transplant immunosuppression.\n* Allergy to Study Drug: Known hypersensitivity to emapalumab or any of its components.\n* Insufficient Baseline Data: Lack of prior baseline FEV1 data for comparison.",{"count":155,"type":21},40,[55],"This study is testing a medication called emapalumab to see if it can help people who have had a lung transplant and are experiencing a sudden drop in lung function, called acute lung allograft dysfunction (ALAD).\n\nALAD is a serious condition that can happen after a lung transplant and can lead to worsening breathing and other complications. Right now, there is no approved treatment for ALAD.\n\nThe main goal is to see if lung function improves, meaning it returns close to your usual (baseline) level within 90 days.",[27],[160,161,27],"ALAD","Acute Lung Allograft Dysfunction","NOT_YET_RECRUITING","2026-04-15",{"date":165,"type":33},"2026-04-20",{"date":167,"type":21},"2026-11-02",{"date":169,"type":21},"2028-11-01",{"name":171,"class":40},"University of California, San Francisco",2,{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":146},"100472001","pre-transplant-health-coaching-to-improve-patient-reported-outcomes-in-lung-transplant-candidates-100472001","NCT05426200","Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates","Inclusion Criteria:\n\n* Waitlisted or deferred for lung transplantation at Mayo Clinic Rochester, Mayo Clinic Florida, or University of Washington\n\nExclusion Criteria:\n\n* Under 18 years old\n* Non-English speaking, nonverbal, or extremely hard of hearing",{"count":180,"type":21},230,[24],"To examine the effectiveness of an individual health coaching intervention for lung transplant candidates. This intervention will include up to 12 health coaching sessions via phone call over a 12-16 week period. This will be compared to a usual care group the receives pre-transplant care and education alone.",[27],[185],"Self-management","2026-03-30",{"date":188,"type":33},"2026-04-03",{"date":190,"type":33},"2023-01-25",{"date":192,"type":21},"2027-01",{"name":145,"class":40},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":41},"100575264","phase-1-bridge-to-lung-transplant-with-trans-septal-extra-corporeal-membrane-oxygenation-ecmo-for-right-heart-failure-from-pulmonary-hypertension-100575264","NCT06770023","Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension","A Pilot Study of Transseptal ECMO With the Protek Solo Cannula in Lung Transplant Candidates With Right Heart Failure From Pulmonary Hypertension","Inclusion Criteria\n\nPatients that are listed for lung transplantation and have:\n\n* PH defined as:\n\n  * Group 1 Pulmonary arterial hypertension (PAH): Mean pulmonary artery pressure (PAP) ≥ 20 mm Hg, pulmonary capillary wedge pressure (PCWP) \\\u003C 15 mm Hg, and pulmonary vascular resistance (PVR) ≥ 3 Wood units\n  * Group 3 PH is defined as the presence of chronic lung disease (CLD) and\u002For hypoxia and mean pulmonary artery pressure (PAP) ≥ 20 mm Hg.\n* Secondary PH (WHO Group 3) or diagnosis of primary PH (WHO Group 1) (to include Eisenmenger syndrome).\n* Failing right ventricle function defined as:\n\n  * a cardiac (CI) index \\\u003C 2.2 L\u002Fmin\u002Fm\\^2 despite continuous infusion of high dose inotropes defined as:\n  * Inhaled nitric oxide \\> 20 ppm and one of the following:\n  * Dobutamine \\> 10 ug\u002Fkg\u002Fmin x 15 minutes or\n  * Milrinone \\> 0.5 ug\u002Fkg\u002Fmin x 120 minutes or\n  * Epinephrine \\> 0.5 ug\u002Fkg\u002Fmin x 15 minutes or\n  * Norepinephrine \\> 0.5 ug\u002Fkg\u002Fmin x 15 minutes and have one of the following:\n\n    1. central venous pressure (CVP) \\> 15 mm Hg\n    2. global RV dysfunction on echocardiography defined as one of the following:\n\n       1. a tricuspid annular plane systolic excursion score of \\\u003C14mm\n       2. an RV diameter at base \\>42mm\n       3. RV short-axis or midcavity diameter \\>35mm\n  * Lactate greater than 3 mmol\u002FL\n  * Urine output \\\u003C 0.5 ml\u002Fkg\u002Fhour\n* Age \\> 18 years old\n* BMI \\\u003C35\n* Informed consent signed by self or legally authorized representative.\n\nExclusion Criteria\n\n* INTERMACS 1 patients (Critical cardiogenic shock patient who is \"crashing and burning\", has life-threatening hypotension and rapidly escalating inotropic or pressor support, with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels)\n* End organ failure defined as: hepatic total bilirubin \\>5 mg\u002FdL based on lab data within 24 hours prior to transseptal ECMO initiation; renal creatinine \\>4 mg\u002FdLbased on lab data within the 24 hours prior to transseptal ECMO initiation\n* Evidence of acute neurologic injury\n* Active infection defined as two of the following WBC \\>12,500, positive blood culture, fever\n* RA thrombus\n* Thrombolysis within the previous 30 days or known existing coagulopathy such as thrombocytopenia or hemoglobin diseases such as sickle cell anemia or thalassemia\n* Right heart failure from isolated pulmonary embolism\n* Right heart failure from coronary artery disease or from left heart failure (WHO Type 2)\n* Congenital forms of pulmonary hypertension such as tetralogy of fallot or pulmonary vein stenosis.",{"count":202,"type":21},4,[204],"PHASE1","The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.",[27,207],"Pulmonary Hypertension",[209],"right heart failure, transseptal, extra-corporeal membrane oxygenation, bridge to transplant","2026-03-26",{"date":212,"type":33},"2026-03-31",{"date":89,"type":21},{"date":215,"type":21},"2028-12",{"name":145,"class":40},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":225,"studyType":81,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":41},"100371613","thoracic-specimen-registry-100371613","NCT04118660","Thoracic Specimen Registry","Inclusion Criteria:\n\n* Subject must be \\> 18 years of age\n* Presumed or known or screening of Thoracic Diseases (which includes but not limited to the following: thoracic neoplasms (masses\u002Fnodules) malignant or benign, interstitial lung diseases (ILD), chronic obstructive pulmonary disease (COPD), thoracic infections, thoracic malignancies metastatic to other organs, other cancers metastatic to the thoracic cavity.",{"count":224,"type":21},7000,"50 Years","The purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors, lung transplants and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases.",[228,229,27],"Thoracic Diseases","Lung Cancer","2026-01-14",{"date":232,"type":33},"2026-01-16",{"date":234,"type":33},"2017-03-01",{"date":236,"type":21},"2028-01",{"name":145,"class":40},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100619137","decreasing-edema-with-a-novel-ocs-solution-trial-100619137","NCT07340710","Decreasing Edema With a Novel OCS Solution Trial","Decreasing Edema With a Novel OCS Solution (DENOVO) Trial","DENOVO","Donor Inclusion\u002FExclusion Criteria\n\nInclusion Criteria:\n\n* Donor lungs are deemed clinically acceptable for transplantation after physical examination of the donor lungs in the donor and\u002For on the back table in the donor operating room.\n* Eligible for randomization to OCS or SCS treatment arms.\n\nExclusion Criteria:\n\n\\- Severe traumatic donor lung injury with air and\u002For blood leak (as seen on radiological studies, bronchial examinations or final visual physical assessment in donor's chest or back table).\n\nRecipient Inclusion\u002FExclusion:\n\nInclusion Criteria:\n\n* Signed informed consent document and authorization to use and disclose protected health information\n* Double lung transplant candidate\n* Age ≥ 18 years old\n\nExclusion:\n\n\\- Participant in any other interventional clinical or investigational trials\u002Fprograms that may confound the outcomes of this trial.",{"count":247,"type":21},450,[24],"This is a prospective, multicenter randomized trial of lung transplant recipients transplanted with either a DBD or DCD donor lungs. The DENOVO Trial will enroll a total of 300 patients in the OCS arm and 150 patients in the SCS arm. The primary endpoint will be patient \\& graft survival and freedom of Primary Graft Dysfunction (PGD) grade 3 within the initial 72 hours post-transplantation.",[27],"2026-01-13",{"date":230,"type":33},{"date":254,"type":21},"2026-03",{"date":256,"type":21},"2028-02",{"name":258,"class":259},"TransMedics","INDUSTRY",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":41},"100510259","a-study-of-latin-dance-for-post--lung-transplant-100510259","NCT05924113","A Study of Latin Dance for Post- Lung Transplant","Efficacy of Latin Dance for Promoting Wellbeing in Post Lung Transplant Recipients as Measured by Several Functional Measures, in the Outpatient Setting","Inclusion Criteria:\n\n\\- Ambulatory with or without assisting devices (not on supplemental oxygen is not exclusionary), who have completed outpatient cardiopulmonary rehab and good pain control.\n\nExclusion Criteria:\n\n\\- Tracheostomy, Hemodialysis, gastro-jejunal tubes, nasogastric tubes, wound vacs, chest tube, high levels of oxygen supplementation (mask vs nasal canula), recent falls.",{"count":268,"type":21},52,[24],"The purpose of this research study is to see if participating in Latin dance for 12 sessions can improve wellbeing in several areas including balance, fear of movement, anxiety, depression and spirometry.",[27,272],"Well-Being, Psychological","2026-01-03",{"date":275,"type":33},"2026-01-06",{"date":277,"type":33},"2023-06-12",{"date":279,"type":21},"2030-12-31",{"name":145,"class":40},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":288,"targetDuration":290,"studyType":81,"phases":4,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":301},"100555515","us-national-top-registry-100555515","NCT06513091","US National TOP Registry","US National OCS Lung Thoracic Organ Perfusion (TOP) Registry","All lung transplant recipients",{"count":289,"type":21},10000,"5 Years","The objective of this Registry is to collect short and long-term post-transplant clinical outcome data of all donor lungs preserved and assessed on the OCS Lung System and to document the performance of the OCS device in the real-world setting after FDA approval in the US.",[27],"2025-09-02",{"date":295,"type":33},"2025-09-03",{"date":297,"type":33},"2025-01-23",{"date":299,"type":21},"2039-11",{"name":258,"class":259},7,{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":41},"100522962","tee-and-dysphagia-in-lung-transplantation-100522962","NCT06089434","TEE and Dysphagia in Lung Transplantation","Transesophageal Echocardiography (TEE) and Dysphagia in Lung Transplantation (LT)","Inclusion Criteria:\n\n1. Adult patients\n2. Single or double lung transplantation\n\nExclusion Criteria:\n\n1. Contraindications to TEE including:\n\n   * perforated esophagus;\n   * esophageal stricture;\n   * esophageal tumor; and\n   * history of an esophagectomy\n2. Patients that require a tracheostomy postoperatively.",{"count":310,"type":21},116,[24],"The primary outcome of this study is dysphagia (difficulty swallowing) on postoperative speech and swallow evaluation following lung transplantation.\n\nTransesophageal echocardiography (TEE) (creates pictures of the heart from inside the participants body) is routinely performed for all lung transplantations at the University of California, Los Angeles (UCLA) and it is the standard of care. Patients are randomized to two groups. The intervention group would limit the number of TEE clips (# pictures taken) per case. The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.\n\nThe investigators hypothesize that reduction in TEE imaging during lung transplantation will reduce dysphagia.",[27,314],"Dysphagia",[316,314,317,318],"Lung Transplantation","Transesophageal Echocardiography (TEE)","Outcomes","2025-07-16",{"date":321,"type":33},"2025-07-18",{"date":323,"type":33},"2024-07-12",{"date":325,"type":21},"2026-07",{"name":327,"class":40},"University of California, Los Angeles",{"id":329,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":25,"conditions":332,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":336,"leadSponsor":337,"locationsCount":41},"100353828",{"count":20,"type":21},[24],[27,28],"2025-07-15",{"date":319,"type":33},{"date":35,"type":33},{"date":37,"type":21},{"name":39,"class":40},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":344,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":41},"100595691","bronchial-response-to-exercise-after-double-lung-transplantation-100595691","NCT07035743","Bronchial Response to Exercise After Double Lung Transplantation","Inclusion Criteria:\n\n1. Received double lung transplantation\n2. ≥ 3 months post-transplant\n\nExclusion Criteria:\n\n1. Diagnosis of asthma\n2. Significant airflow limitation (≤50% FEV1 predicted)\n3. Inability to cooperate with the required tests and measurements\n4. Recent infection or rejection within 1 month\n5. Exercise contraindication (e.g., recent heart attack or stroke within 3 months, uncontrolled hypertension, known aortic aneurysm, unstable cardiac ischemia, malignant arrhythmias)","20 Years",{"count":155,"type":21},"This study aims to investigate the airway response to exercise and its association with breathlessness in double lung transplant recipients by comparing responses during 5-minute and 15-minute exercise durations.",[348,349,27,350],"Airway Response","Lung Transplant Recipients","Challenge Test",[352,353,354,355,356],"airway response","double lung transplantation","exercise challenge test","dyspnea","breathlessness","2025-06-16",{"date":359,"type":33},"2025-06-25",{"date":361,"type":33},"2025-06-05",{"date":363,"type":21},"2025-12-31",{"name":365,"class":40},"Chang Gung Memorial Hospital",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":41},"100483954","a2-to-o-lung-transplants-100483954","NCT05581745","A2 to O Lung Transplants","Blood Group A2 Donor to Blood Group O Recipient Lung Transplantation","Inclusion Criteria:\n\n* first lung transplant\n* blood group O recipient\n* low pre-operative anti-A antibody titers\n* consent to study participation\n\nExclusion Criteria:\n\n* re-transplant\n* multiorgan transplant\n* positive virtual crossmatch at time of transplant",{"count":374,"type":21},10,[24],"Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.",[27,378],"ABO Incompatibility","2025-02-03",{"date":381,"type":33},"2025-02-06",{"date":383,"type":33},"2022-07-14",{"date":385,"type":21},"2033-12-31",{"name":387,"class":40},"University Health Network, Toronto",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":396,"targetDuration":290,"studyType":81,"phases":4,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":41},"100490881","dream-double-lung-transplant-registry-aimed-for-lung-limited-malignancies-100490881","NCT05671887","DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies","Double Lung Transplant REgistry Aimed for Lung-limited Malignancies (DREAM) - a Prospective Observational Registry Study for Patients Undergoing Lung Transplantation for Medically Refractory Cancers Confined to the Lungs","DREAM","Inclusion Criteria:\n\nAny patient who is undergoing double lung transplantation as part of the clinical program, consents for this prospective observational trial, and has one of the following conditions will be eligible.\n\n* Common Inclusion Criteria\n\n  * Adults of Age ≦ 80\n  * Resistant or refractory to or without available standard of care treatment options or experimental treatment options that are known to increase survival outcome\n  * Patients without any extrapulmonary disease\n  * Patients with good general health with an ability to withstand physiologic stressors and undergo psychosocial evaluation by the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) or other assessment tools\n  * Patients to meet all other criteria for lung transplantation including insurance approval and United Network for Organ Sharing (UNOS) registration\n\nInclusion Criteria for Cohort A\n\n* Histologically confirmed selected lung non-small cell lung cancer including but not limited to:\n\n  o according to the International Association for the Study of Lung Cancer (IASLC)\u002FAmerican Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS) classification\n\n  \\- Lepidic dominant pattern\n* Adenocarcinoma in situ\n* Minimally invasive adenocarcinoma\n* Non mucinous lepidic predominant invasive adenocarcinoma\n\n  o based on 2015 World Health Organization (WHO) classification of lung tumors including\n\n  \\- Invasive mucinous adenocarcinoma\n* Mixed invasive mucinous and mucinous adenocarcinoma\n\n  * Colloid adenocarcinoma\n  * Enteric adenocarcinoma\n  * Minimally invasive adenocarcinoma\n* Nonmucinous\n* Mucinous\n\n  \\- Preinvasive lesions\n* Atypical adenomatous hyperplasia\n* Adenocarcinoma in situ\n\n  * Nonmucinous\n  * Mucinous\n  * based on the 2004 WHO classification of lung tumors including - Bronchioloalveolar carcinoma\n* Nonmucinous\n* Mucinous\n* Mixed nonmucinous and mucinous or indeterminate\n* Without any distant metastasis confirmed by standard staging work-up\n* Without brain metastasis confirmed by brain imaging\n* Without unidentified primary site of cancer\n\nInclusion Criteria for Cohort B\n\n* Metastatic cancers to lung alone - including but not limited to germ cell tumors, head \\& neck tumors, colorectal tumors, renal cell tumors, testicular cancer\n* Without any other distant metastasis confirmed by standard staging work-up\n\nInclusion Criteria for Cohort C\n\n* Respiratory failure with a history of cancer in the last 5 years - including, but not limited to interstitial lung disease (ILD), pulmonary fibrosis (idiopathic or secondary), advanced chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH)\n* Without any other distant metastasis confirmed by standard staging work-up\n\nExclusion Criteria:\n\n* Exclusion criteria\n\n  * Adults unable or unwilling to consent\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Pregnant women\n  * Prisoners\n  * Vulnerable Populations\n  * Presence of extrapulmonary disease or mediastinal nodal disease at the time of transplant referral\n  * Small Cell Cancers\n  * Unidentified primary site of cancer for Cohort A\n  * Progression of disease or confirmed distant metastases or mediastinal nodal disease at any point during transplantation work-up\n  * Medical ineligibility for lung transplantation after multidisciplinary assessment\n  * Not a suitable candidate according to the lung transplantation protocol for treatment of lung confined primary or metastatic tumors\n* Body mass index more than 35 kg\u002Fm2\n* Evidence of co-existing malignancies for Cohort A\n* Untreatable significant dysfunction of another major organ system including heart, liver, kidney, or brain unless combined organ transplantation can be performed\n* Uncorrected atherosclerotic disease with suspected or confirmed end-organ ischemia or dysfunction and\u002For coronary artery disease not amenable to revascularization\n* Uncorrectable bleeding diathesis\n* Evidence of active Mycobacterium tuberculosis infection\n* Significant chest wall or spinal deformity expected to cause severe restriction after transplantation",{"count":397,"type":21},125,"This is a prospective observational registration trial for patients who undergo lung transplantation for the treatment of the select groups of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.",[229,400,27],"Bilateral Cancer",[402,229,400,27,403,404,405,406],"Cancer","Double Lung Transplant","Bronchioloalveolar Carcinoma (BAC)","Lepidic","Mucinous","2024-11-12",{"date":409,"type":33},"2024-11-14",{"date":411,"type":33},"2022-11-16",{"date":413,"type":21},"2032-11",{"name":415,"class":40},"Northwestern University"]